Anti-inflammatory Therapy for Acute Lung Injury Craig Metz, Ph.D. CHEST Volume 100, Issue 4, Pages 1110-1119 (October 1991) DOI: 10.1378/chest.100.4.1110 Copyright © 1991 The American College of Chest Physicians Terms and Conditions
FIGURE 1 Major features in progression of animal and clinical pulmonary injury. TxB2, Thromboxane B2; PGI2, prostaglandin I2; HR, heart rate; FIo2, inspired oxygen tension; a/ao2 gradient, alveolar-arterial oxygen tension gradient; PMN, polymorphonuclear neutrophil Pa, mean arterial perfusing pressures; PEEP, positive end-expiratory pressure; LP/TP, lymph-to-plasma total protein ratios; CO, cardiac output; PMP, pulmonary microvascular permeability; and MPSS, methyprednisolone sodium succinate. CHEST 1991 100, 1110-1119DOI: (10.1378/chest.100.4.1110) Copyright © 1991 The American College of Chest Physicians Terms and Conditions
FIGURE 2 Diagrammatic representation of arachidonic acid cascade, demonstrating where various anti-inflammatory agents discussed would modify production of vasoconstrictor and vasodilator prostaglandins. CHEST 1991 100, 1110-1119DOI: (10.1378/chest.100.4.1110) Copyright © 1991 The American College of Chest Physicians Terms and Conditions